High debt companies and long term stock returns.

Jan 01 2015 : The Economic Times (Mumbai)
High-Debt Cos Fail to Gain from Bull Runs


Here's a word of caution as you go about picking stocks in a market that some say has run ahead of reality. While it's generally said that holding stocks for a long time would give good returns, there is a flip side to the common refrain in the world of investments. In the last 10 years, Indian equity market has witnessed three bull runs, including the recent one. But, there is a long list of BSE500 companies that have not generated meaningful returns in this period.Companies such as Future Retail, Tata Steel, Ranbaxy , Hindalco, Reliance Infrastructure, Videocon Industries, Jubilant LifeSciences, JP Associates, IDBI Bank and HCL Infosystems have given returns ranging from 34% to 25% in the last 10 years (see chart). This means even the best performing stock of the lot rose just 2% annually . This is despite their sales growing multi-fold. Take Hindalco, for instance. Its sales surged from `8,223 crore in FY04 to `87,228 crore in FY14; but, the stock has gained only 25% in the period. Similar is the story with most other companies.
The common thread -and also a key takeaway for investors -is that most of these companies (excluding banks) had, and continue to have, high debt, which, more than anything else, contributed to their dismal performance, with the cost of debt eating into profits and cash flows.

Comments

Post a Comment

Popular posts from this blog

Aab Tak Chhapan, Aab Nahi to Kab?

Image
I am 56, if not now then when? "If I can, anybody can". India has become the capital of Obesity, Diabetes and Osteoporosis  due to lack of motivation for Outdoor activity. "If you Desire change, change yourself first". I used to advise patients to opt for a active outdoor life. But nobody listened. As a Surgeon at 56, aspiring to be a role model for wellness and fitness I participated in the Polar Fjallraven 2018 contest. Few years back on reaching 50s, I had lot of problems. Syndrome X, Midlife crisis, Mid WAIST crisis, Mid leg crisis and what not. I had the option of taking the Stick – wooden, aluminium, medicine !! I opted for two sticks instead of one. The stick of Running and Hiking. Over the past five years I have played Squash, Lifted weights done a few Half Marathons,Skied and Trekked. Local treks ( Ghatkopar Tekddi, Mulund Tekddi, Sahayadri Ghats and Forts and then high altitude mountain treks in India and Nepa...
Read more

#celebrating60s. Atmanirbhar 41 kms run. 5 th Dec 2021

#celebrating60s Atmanirbhar 41 kms run. Self supported Run. Nutrition, hydration, illumination and music all carried on back. Thanks K Sanjay Singh for giving company in the last 5 kms, pacing and helping me climb the "wall". I dedicate the Run to Dr Pranesh Patil Gaikwad, senior Anesthetist Ghatkopar, fellow runner, co trekker, and travel buddy, with a prayer.. recover soon dear friend. I continuously prayed for him during the run and could finish the run smoothly. The collective prayer of all will smoothen his recovery. We have travelled to many places together, but many are still on the bucket list. Recover soon Patil so I can begin planning.
Read more

Cipla Embraces Gilead and a New Era as Priorities Change

Cipla Embraces Gilead and a New Era as Priorities Change Divya Rajagopal Mumbai:   Once a steadfast backer of generics, co now enters into a deal to make Hepatitis drug for MNC ruary last year Hamied had said  In an interview to ET in 2013, YK Hamied, the founder chairm an of Cipla, and some say the scourge of multinational drug companies, prophesied that the Indian drug industry will witness a sea change around the year 2020.“The momentum of 1972 to 1995 (pre-patent era) can't stop . It will last till 2015, but not after that. So to protect myself for 2020 I have to make radical changes.“ On Monday , the world got a glimpse of the kind of change that Hamied had in mind when Cipla teamed up with California-based Gilead Lifesciences to make and sell its path-breaking Hepatitis C drug Sofosbuvir under voluntary licence. On the face of it, there is nothing wrong with this kind of a deal.Pharma companies ink many such pacts on a regular basis. But what...
Read more